Our team helps you every step of the way
FirstStepDx PLUS includes a Chromosomal Microarray (CMA) that can identify an underlying genetic cause in individuals with developmental delay, intellectual disability, and autism spectrum disorder. Lineagen makes genetic testing easy and accessible for everyone. Your patient's sample is collected with a painless, non-invasive cheek swab, and Lineagen handles all of the insurance correspondence followed by delivery of a thorough, yet easy-to-read report.
FirstStepDx PLUS Chromosomal Microarray (CMA) testing service includes:
Optimization of the FirstStepDx PLUS CMA results in a 30% detection rate of clinically relevant results, the highest detection rate of any clinically available CMA test.
FirstStepDx PLUS can detect an underlying genetic cause of developmental delay, which means opening up new treatment options and pointing towards necessary evaluations. A CMA can pinpoint one of hundreds of known conditions that may be responsible for your patient's clinical features, which treatments should be considered, including evaluations for co-occurring medical issues, and recurrence risk for the family.
FirstStepDx PLUS Chromosomal Microarray (CMA) is optimized with unique detection sites1, 2 to increase detection rate, as well as rule out many other conditions.
Our genetic counselors explain the test results in a thorough, but easy-to-understand report. Even if this is your first genetic test, you'll have no trouble understanding the results and advising parents on their options.
The report also includes a section for parents and, if there are any questions, you have unlimited access to our genetic counselors.
For some healthcare providers, the most challenging part of ordering a genetic test is the long process of authorizations and appeals.
Lineagen takes the insurance burden from providers and their staff by assisting in every step of the process. This way providers can focus on direct patient care.